国际妇产科学杂志Issue(3)：232-235,4.
白蛋白结合型紫杉醇在妇科肿瘤中的研究进展
Research Progress of Albumin-bound Paclitaxel in Gynecologic Oncology
曾靖 1张蓉1
作者信息
- 1. 100021 北京，中国医学科学院北京协和医学院肿瘤医院肿瘤研究所妇瘤科
- 折叠
摘要
Abstract
Albumin-bound paclitaxel is a novel formulation of paclitaxel with albumin as its solvent. Compare to the conventional paclitaxel formulation (solvent is polyoxyethylene castor oil and ethanol),its anti-tumor capability is more effective and hematologic toxicity ,severe allergic reaction and other side effects are less. In recent years ,albumin-bound paclitaxel are widely used on clinical studies of gynecologic oncology. There are three Phase Ⅱ clinical studies currently reported on ovarian cancer,nanoparticle albumin-bound paclitaxel in platinum-sensitive patients and platinum-resistant patients with ovarian,peritoneal,or fallopian tube canceral and bevacizumab with albumin-bound paclitaxel in patients with recurrent,platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma,which have shown the efficacy and tolerated adverse reactions. The study reported a phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer and point out that albumin-bound paclitaxel is a considering drug with little side effects. In short ,there is only a few study on albumin-bound paclitaxel in gynecologic oncology until now and we need more further study.关键词
紫杉酚/宫颈肿瘤/卵巢肿瘤/子宫肿瘤/癌/肉瘤Key words
Paclitaxel/Uterine cervical neoplasms/Ovarian neoplasms/Uterine neoplasms/Carcinoma/Sarcoma引用本文复制引用
曾靖,张蓉..白蛋白结合型紫杉醇在妇科肿瘤中的研究进展[J].国际妇产科学杂志,2014,(3):232-235,4.
